In a world of increasing resistance emerges a hope to eradicate Helicobacter pylori: Vonoprazan

Kaynakça (3)

1. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9(Suppl 2): 33
2. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guideline on the Manage-ment of Helicobacter pylori Infection. Am J of Gastroen-terol 2007; 102: 1808-25. [CrossRef] 3. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; pii: gutjnl-2015-311304
3. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-71. [CrossRef] 5. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithro-mycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clar-ithromycin. Aliment Pharmacol Ther 1998; 12: 383-8. [CrossRef] 6. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17: 3971-5. [CrossRef] 7. de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppres-sion on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-9.